Davidson Matt — SEC Form 4 Insider Trading Activity
Summary
Updated Jul 16, 2026
Davidson Matt has filed 1 SEC Form 4 filing across 1 company in the last 90 days.
Profile
Davidson Matt is a biotechnology executive who, according to the latest SEC filing dated 2026-06-16, serves as Chief Development Officer of Adial Pharmaceuticals, Inc. In this role, he is responsible for overseeing development activities at the company, including strategy for clinical development and regulatory interactions. The SEC filing provides no additional biographical details such as education, career history, or prior roles.
Role
Chief Development Officer, Director
Notability
15/100
Board memberships
Adial Pharmaceuticals, Inc.
Awards & honors
Listed as Chief Development Officer at Adial Pharmaceuticals, Inc. in SEC filing dated 2026-06-16.
Davidson Matt is a biotechnology executive who, according to the latest SEC filing dated 2026-06-16, serves as Chief Development Officer of Adial Pharmaceuticals, Inc. In this role, he is responsible for overseeing development activities at the company, including strategy for clinical development and regulatory interactions. The SEC filing provides no additional biographical de…
How many SEC Form 4 filings has Davidson Matt submitted recently?
1 primary Form 4 filings in the last 90 days, covering 1 company.
Where can I see all of Davidson Matt's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
